Date: 2015-09-18
Type of
information: Presentation of results at a congress
phase: preclinical, 2
Announcement: presentation of results at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference taking place September 16-19, 2015 in New York City.
Company: Ziopharm Oncology (USA - MA)
Product: Ad-RTS-IL-12
Action
mechanism:
- gene therapy. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response.
Disease: advanced melanoma, breast cancer, glioblastoma, colon cancer
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On September 18, 2015, Ziopharm Oncology, a biopharmaceutical company focused on the development and commercialization of new cancer immunotherapies, announced the presentation of clinical and preclinical data from the Company's Ad-RTS-IL-12 program in various malignancies at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference taking place September 16-19, 2015 in New York City. The first poster presentation, titled, Demonstration of systemic antitumor immunity via intratumoral regulated expression of IL-12 in advanced breast cancer and melanoma patients" highlights additional evidence of systemic immune activation with AD-RTS-hIL-12 and veledimex in advanced melanoma and breast cancer patients. The data were drawn from two previously completed open-label Phase II clinical studies: one which enrolled 12 patients with metastatic advanced stage breast cancer, and one which enrolled 26 patients with metastatic melanoma, both exploring the immune-mediated local and systemic anti-tumor effects of Ad-RTS-hIL-12 and veledimex. Among other findings, treatment with Ad-RTS-hIL-12 and veledimex in patients with melanoma was found to increase in the immune cytokine IL-12 and downstream cytokines, IFNg, IP-10 and IL-10, resulting in a significant increase in tumor infiltrating lymphocytes both locally, in injected lesions, and systemically, in non-injected lesions.
- The second poster presentation, titled Demonstration of systemic antitumor immunity via intratumoral regulated expression of IL-12 as a gene therapy approach to treatment of cancer demonstrates the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in murine models of glioblastoma (brain cancer), colon cancer and melanoma. The data demonstrated dose-related increases in veledimex in both plasma and brain tissue, leading to an increase in expression of IL-12 mRNA and in-tumor IL-12p70 expression with minimal increase in serum IL-12. Ad-RTS-mIL-12 + veledimex also demonstrated systemic memory upon rechallenge in multiple syngeneic mouse models, providing further evidence of systemic anti-tumor immunity elicited by Ad-RTS-mIL-12.
Is
general: Yes
